---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088195"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:43.642189+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enliven reports Q4/FY2025 results; initial Phase 1b data for ELVN-001 shows MMR rates 47-69%

## Summary
- Net loss of $29.7M for Q4 2025 vs $23.2M for Q4 2024; full year net loss $103.7M vs $89.0M.
- Cash, equivalents and marketable securities $462.6M, providing runway into first half of 2029.
- Initial Phase 1b data: MMR achieved in 47% (80 mg QD) and 69% (60/120 mg QD) of evaluable patients.
- Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected to initiate in second half of 2026.
- Rick Fair appointed CEO in December 2025; Scott Garland added to board in January 2026.

## SEC filing metadata
- accession: 0001193125-26-088195
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/0001193125-26-088195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088195
- JSON: https://secwatch.observer/filing/0001193125-26-088195.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088195.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.